Rare Cancers – more common than you think
ESMO Sarcoma & GIST 2018: Round table with SPAEN
More than 4.3 million people in the European Union are affected by rare cancers. Despite the rarity of each of the 198 rare cancers, they represent in total about 22% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
29 Aug 2018
Rare Cancers Europe 10th anniversary event at the European Parliament
Rare Cancers Europe: 10 years of cooperation to improve care for cancer patients
-
22 Feb 2018
ESMO eUpdate – Medullary Thyroid Cancer Treatment Recommendations
Featuring the ESMO-MCBS grading & treatment recommendations
-
21 Feb 2018
Ten years and counting: rare cancers are not so rare anymore
RCE article in the February 2018 edition of the Parliament Magazine